JAMA Network
About The Study: At the lesion level, very intensive lipid-lowering therapy induced substantially greater percent atheroma volume regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion minimum lumen area and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
